CeGaT GmbH announced today the delivery of the first of two Illumina NovaSeq 6000 systems to further support its production scale for both clinical and translational research.
Joining CeGaT’s fleet of HiSeq® 4000, HiSeq 2500, and MiSeq® instruments, the newest Illumina platform released in March 2017 – NovaSeq 6000 instrument with S2 flowcell configuration – can now sequence up to 130 human exomes in 29 hours. That is an increase in output by 30% and twice faster than the HiSeq 4000 platform. By the end of 2017 when the S4 flowcell will be launched, the capability of sequencing 50 human genomes in approximately 2 days will pave the way towards future advances in clinical genomics and precision medicine. With the implementation of NovaSeq, CeGaT can shorten the turnaround time from sample to data and offer its customers the state-of-the-art sequencing technology.
Since it was founded in 2009 CeGaT has pioneered the approach of combining genetic diagnostics with NGS by offering various large diagnostic panels. Trio exome diagnostics, whole genome, and whole transcriptome have been added to an already extensive NGS portfolio. Different flavors of RNA-Seq, ranging from normal- to low-input or at the single-cell level, long or small RNA, coding or non-coding RNA, can all be done at CeGaT. An integrative genomics approach by combining whole exome and whole transcriptome can further provide clinically actionable information that could impact treatment decisions. Each method has been adapted to challenging material, i.e. FFPE, cell-free DNA, CTC, LCM, or degraded samples.
Have you heard about our limited-time offer? – Exome sequencing for your research projects. Starts at 333€. Learn more >